No black box warning on record for Clindamycin Phoaphate Topical Usp, 1%

As of the latest FDA labeling reviewed, Clindamycin Phoaphate Topical Usp, 1% (CLINDAMYCIN PHOSPHATE TOPICAL USP, 1%) does not carry a black box warning. Standard warnings and precautions still apply — see the full Clindamycin Phoaphate Topical Usp, 1% medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. Studies indic

No black box warning on record for Clindamycin Phoaphate Topical Usp, 1%

Other warnings & precautions

WARNINGS Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. Studies indic

Clindamycin Phoaphate Topical Usp, 1% Black Box Warning

No black box warning on record for Clindamycin Phoaphate Topical Usp, 1%

Other warnings & precautions

Clindamycin Phoaphate Topical Usp, 1% Black Box Warning

No black box warning on record for Clindamycin Phoaphate Topical Usp, 1%

Other warnings & precautions